loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Tisotumab Vedotin

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Tisotumab Vedotin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tisotumab Vedotin Active In Recurrent/Metastatic HNSCC Patients
    Tisotumab Vedotin Active In Recurrent/Metastatic HNSCC Patients

    03 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240603640244/en

    BUSINESSWIRE
    03 Jun 2024
    Share Share
    Tisotumab Vedotin Shows Activity In Recurrent/Metastatic HNSCC
    Tisotumab Vedotin Shows Activity In Recurrent/Metastatic HNSCC

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892268/0/en/Investigational-Tisotumab-Vedotin-Phase-2-Data-Demonstrates-Encouraging-Antitumor-Activity-in-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Squamous-Cell-Carcinoma-HNSCC.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    US FDA grants full approval for Pfizer's cervical cancer drug
    US FDA grants full approval for Pfizer's cervical cancer drug

    30 Apr 2024

    // Pratik Jain REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-grants-full-approval-pfizers-cervical-cancer-drug-2024-04-29/

    Pratik Jain REUTERS
    30 Apr 2024
    Share Share
    TIVDAK® Approved by FDA for Recurrent/Metastatic Cervical Cancer
    TIVDAK® Approved by FDA for Recurrent/Metastatic Cervical Cancer

    29 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/29/2871730/0/en/TIVDAK-tisotumab-vedotin-tftv-Receives-U-S-FDA-Approval-to-Treat-Recurrent-or-Metastatic-Cervical-Cancer.html

    GLOBENEWSWIRE
    29 Apr 2024
    Share Share
    TIVDAK sBLA Accepted for Priority Review by FDA for Cervical Cancer
    TIVDAK sBLA Accepted for Priority Review by FDA for Cervical Cancer

    09 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/09/2806100/0/en/TIVDAK-tisotumab-vedotin-tftv-Supplemental-Biologics-License-Application-Accepted-for-Priority-Review-by-U-S-Food-and-Drug-Administration-for-Patients-with-Recurrent-or-Metastatic-.html

    GLOBENEWSWIRE
    09 Jan 2024
    Share Share
    TIVDAK sBLA Application Accepted for Priority Review by FDA for Cervical Cancer
    TIVDAK sBLA Application Accepted for Priority Review by FDA for Cervical Cancer

    09 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240105049976/en

    BUSINESSWIRE
    09 Jan 2024
    Share Share